WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Sreemantula Divya*, Akula Amulya, Ayesha Fathima, Gariga Deekshitha, Dr. G. Damodhar Reddy, Dr. Hadiya Iram

ABSTRACT

Heart failure is a global public health concern that occurs in more than 26 million people globally. The aim and objective of the study to evaluate effect of Dapagliflozin on improving ejection fraction in heart failure patients with reduced ejection fraction (HFrEF) and to check an secondary outcomes and quality of life in heart failure patients after the treatment. The study design is a prospective and retrospective single center observational study. It was conduct in Medicover hospitals (Tertiary care hospital), Hi-Tech city, Hyderabad with sample size 100 patients or more in the duration of 6 months. The results are evaluated as Dapagliflozin is commonly used in heart failure patients with reduced ejection fraction (HFrEF) — even in those without diabetes. The most common symptoms were SOB (56.86%), Chest pain (30.39%) and pedal edema (3.92%). The majority symptom and comorbidity associated with HFrEF was found to be SOB and HTN which was observed in 58 patients out of 102 patients. The most common comorbidity was HTN (53.92%), DM-2 (29.42%), CAD (4.90%), Hypothyroidism (4.90%). The impact of Dapagliflozin(10mg) in increasing LVEF % was increase from 38.87 % to 58.23 %. Majority of patients before the treatment with Dapagliflozin were observed a Grade 2 to Grade 4 with the analysement of symptoms by the reduction of this Dapagliflozin therapy overall a quality of life. The study was concluded as its positive effects on cardiac structure, symptoms, and metabolic parameters illustrate its value as an adjunct in managing heart failure, particularly in those with metabolic comorbidities.

[Full Text Article] [Download Certificate]